AK Medical Holdings Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, AK Medical Holdings stock has a consensus rating of "Strong Buy" and an average price target of $8.15. The average 1-year stock price forecast is 50.09% higher than the current stock price, while the lowest is $7.67 (+41.25%) and the highest is $8.60 (+58.38%).

Price Target: $8.15 (+50.09%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.67	$8.15	$8.17	$8.60
Change	+41.25%	+50.09%	+50.46%	+58.38%

* Price targets were last updated on Apr 26, 2026.

Analyst Ratings

The average analyst rating for AK Medical Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	5	5	5	4	5	6
Buy	0	0	0	0	0	0
Hold	0	0	0	1	1	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Chris Pan Goldman Sachs	Goldman Sachs	Buy Maintains $8.40	Buy	Maintains	$8.40	+54.70%	Apr 26, 2026
David Shang Jefferies	Jefferies	Buy Maintains $7.50	Buy	Maintains	$7.50	+38.12%	Mar 31, 2026
Unknown Analyst CICC No rating	CICC	Buy Maintains $7.63	Buy	Maintains	$7.63	+40.52%	Mar 30, 2026
Unknown Analyst GF Securities No rating	GF Securities	Buy Maintains $8.48	Buy	Maintains	$8.48	+56.17%	Mar 28, 2026
Unknown Analyst Huatai Securities No rating	Huatai Securities	Buy Maintains $8.41	Buy	Maintains	$8.41	+54.88%	Mar 28, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.66B

from 1.48B

11.99%

from 1.48B

Revenue Next Year

1.85B

from 1.66B

11.33%

from 1.66B

EPS This Year

0.35

from 0.30

16.34%

from 0.30

EPS Next Year

0.41

from 0.35

17.02%

from 0.35

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	761.44M	1.05B	1.09B	1.35B	1.48B	1.66B
Revenue Growth	-26.46%	38.17%	3.98%	23.09%	10.11%	11.99%
Gross Profit	499.19M	636.44M	674.49M	808.19M	897.40M	1.02B
Gross Margin	65.56%	60.49%	61.66%	60.03%	60.54%	61.48%
Operating Income	99.44M	238.34M	211.48M	300.78M	373.88M	426.60M
Net Income	92.62M	204.77M	182.10M	273.93M	339.09M	396.44M
EPS	-	-	-	-	0.30	0.35
EPS Growth	-	-	-	-	26.25%	16.34%
Forward PE	32.47	32.47	32.47	32.47	32.47	13.31
Dividend / Share	0.02	0.05	0.04	0.07	0.11	0.10
Dividend Growth	-	160.59%	-23.04%	65.64%	56.73%	-8.83%
Free Cash Flow	40.55M	129.07M	-154.43M	285.75M	-23.63M	405.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue	2026	2027	2028
High	1.7B
Avg	1.7B
Low	1.6B

Revenue Growth

Revenue Growth	2026	2027	2028
High	13.7%
Avg	12.0%
Low	10.8%

EPS Forecast

EPS	2026	2027	2028
High	0.37
Avg	0.35
Low	0.31

EPS Growth

EPS Growth	2026	2027	2028
High	22.1%
Avg	16.3%
Low	2.3%